Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin

A wide variety of drugs bind to human serum albumin (HSA) at its two principal sites, namely site I and site II. A number of reports indicate that drug binding to these two binding sites are not completely independent, and that interactions between ligands of these two discrete sites can play a role. In this study, the effect of the binding of long-chain fatty acids on the interactive binding between dansyl-L-asparagine (DNSA; site I ligand) and ibuprofen (site II ligand) at pH6.5 was examined. Binding experiments showed that the binding of sodium oleate (Ole) to HSA induces conformational changes in the molecule, which, in turn, changes the individual binding of DNSA and ibuprofen, as well as the mode of interaction between these two ligands from a ‘competitive-like’ allosteric interaction in the case of the defatted HSA conformer to a ‘nearly independent’ binding in the case of non-defatted HSA conformer. Circular dichroism measurements indicated that ibuprofen and Ole are likely to modify the spatial orientation of DNSA at its binding site. Docking simulations suggest that the long-distance electric repulsion between DNSA and ibuprofen on defatted HSA contributes to a ‘competitive-like’ allosteric interaction, whereas extending the distance between ligands and/or increasing the flexibility or size of the DNSA binding site in fatted HSA evokes a change in the interaction mode to ‘nearly independent’ binding. The present findings provide further insights into the structural dynamics of HSA upon the binding of fatty acids, and its effects on drug binding and drug-drug interactions that occur on HSA.

[1]  J. Chamani,et al.  Investigation of the Interaction Between Human Serum Albumin and Two Drugs as Binary and Ternary Systems , 2015, European Journal of Drug Metabolism and Pharmacokinetics.

[2]  J. Chamani,et al.  A comparison study of the interaction between β-lactoglobulin and retinol at two different conditions: spectroscopic and molecular modeling approaches , 2015, Journal of biomolecular structure & dynamics.

[3]  J. Chamani,et al.  Probing the interaction of lysozyme with ciprofloxacin in the presence of different-sized Ag nano-particles by multispectroscopic techniques and isothermal titration calorimetry , 2014, Journal of biomolecular structure & dynamics.

[4]  Toru Maruyama,et al.  Albumin-drug interaction and its clinical implication. , 2013, Biochimica et biophysica acta.

[5]  J. Hamilton,et al.  Correspondence of fatty acid and drug binding sites on human serum albumin: a two-dimensional nuclear magnetic resonance study. , 2013, Biochemistry.

[6]  V. Trezza,et al.  Human serum albumin: from bench to bedside. , 2012, Molecular aspects of medicine.

[7]  S. Curry,et al.  Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin , 2011, Journal of structural biology.

[8]  P. Ascenzi,et al.  Ibuprofen binding to secondary sites allosterically modulates the spectroscopic and catalytic properties of human serum heme–albumin , 2011, The FEBS journal.

[9]  S. Urien,et al.  A re-evaluation of the HSA-piroxicam interaction , 1990, European Journal of Drug Metabolism and Pharmacokinetics.

[10]  G. J. van der Vusse Albumin as fatty acid transporter. , 2009, Drug metabolism and pharmacokinetics.

[11]  S. Curry,et al.  Lessons from the crystallographic analysis of small molecule binding to human serum albumin. , 2009, Drug metabolism and pharmacokinetics.

[12]  G. J. Vusse Albumin as Fatty Acid Transporter , 2008 .

[13]  M. Sadeghi,et al.  Calorimetric and Binding Dissections of HSA Upon Interaction with Bilirubin , 2006, The protein journal.

[14]  P. Ascenzi,et al.  Allosteric modulation of anti‐HIV drug and ferric heme binding to human serum albumin , 2005, The FEBS journal.

[15]  P. Ascenzi,et al.  Heme impairs allosterically drug binding to human serum albumin Sudlow's site I. , 2005, Biochemical and biophysical research communications.

[16]  M. Otagiri,et al.  Interaction Mechanism Between Indoxyl Sulfate, a Typical Uremic Toxin Bound to Site II, and Ligands Bound to Site I of Human Serum Albumin , 2001, Pharmaceutical Research.

[17]  E. Ravussin,et al.  A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM , 1995, Diabetologia.

[18]  K. Giacomini,et al.  Correction for Volume Shift during Equilibrium Dialysis by Measurement of Protein Concentration , 1984, Pharmaceutical Research.

[19]  C. Sorenson,et al.  Electrochemical Evidence for the Molten Globule States of Cytochrome c Induced by N-Alkyl Sulfates at Low Concentrations , 2003, Journal of protein chemistry.

[20]  M. Otagiri,et al.  Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. , 2002, Biological & pharmaceutical bulletin.

[21]  S. Curry,et al.  Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. , 2001, Journal of molecular biology.

[22]  S. Curry,et al.  Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. , 2000, Journal of molecular biology.

[23]  D C Carter,et al.  Conformational Transitions of the Three Recombinant Domains of Human Serum Albumin Depending on pH* , 2000, The Journal of Biological Chemistry.

[24]  M. Otagiri,et al.  Interactive binding to the two principal ligand binding sites of human serum albumin: effect of the neutral-to-base transition. , 1999, Biochimica et biophysica acta.

[25]  P. Brick,et al.  Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites , 1998, Nature Structural Biology.

[26]  T. Peters,et al.  All About Albumin: Biochemistry, Genetics, and Medical Applications , 1995 .

[27]  G. Gerber,et al.  Membrane permeation and intracellular trafficking of long chain fatty acids: insights from Escherichia coli and 3T3-L1 adipocytes. , 1995, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[28]  D C Carter,et al.  Structure of serum albumin. , 1994, Advances in protein chemistry.

[29]  B. Testa,et al.  Human Serum Albumin Conformational Changes as Induced by Tenoxicam and Modified by Simultaneous Diazepam Binding , 1993, The Journal of pharmacy and pharmacology.

[30]  O. Sejersted,et al.  Effect of exercise on recovery changes in plasma levels of FFA, glycerol, glucose and catecholamines. , 1991, Acta physiologica Scandinavica.

[31]  H. Yamada,et al.  Structural transition of bovine plasma albumin in the alkaline region--the N-B transition. , 2009, International journal of peptide and protein research.

[32]  P. McNamara,et al.  Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam. , 1990, Biochemical pharmacology.

[33]  A. O. Pedersen,et al.  Multiple fatty acid binding to albumin in human blood plasma. , 1990, European journal of biochemistry.

[34]  M. Fischer,et al.  The molecular mechanism of the neutral-to-base transition of human serum albumin. Acid/base titration and proton nuclear magnetic resonance studies on a large peptic and a large tryptic fragment of albumin. , 1989, The Journal of biological chemistry.

[35]  U. Kragh-Hansen,et al.  Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands. , 1988, Molecular pharmacology.

[36]  T. Horie,et al.  Influence of the N-B transition of human serum albumin on the structure of the warfarin-binding site. , 1987, Biochimica et Biophysica Acta.

[37]  J. Wilting,et al.  A study on the allosteric interaction between the major binding sites of human serum albumin using microcalorimetry. , 1985, Biochimica et biophysica acta.

[38]  H. Bunn,et al.  Nonenzymatic glycosylation of human serum albumin alters its conformation and function. , 1984, The Journal of biological chemistry.

[39]  S. Wanwimolruk,et al.  The effects of N-B transition of human serum albumin on the specific drug-binding sites. , 1982, Biochimica et biophysica acta.

[40]  J. Wilting,et al.  A comparative study of some physico-chemical properties of human serum albumin samples from different sources--II. The characteristics of the N-B transition and the binding behaviour with regard to warfarin and diazepam. , 1982, Biochemical pharmacology.

[41]  U Kragh-Hansen,et al.  Molecular aspects of ligand binding to serum albumin. , 1981, Pharmacological reviews.

[42]  S. Chakrabarti Cooperativity of warfarin binding with human serum albumin induced by free fatty acid anion. , 1978, Biochemical pharmacology.

[43]  T. Sjödin Circular dichroism studies on the inhibiting effect of oleic acid on the binding of diazepam to human serum albumin. , 1977, Biochemical pharmacology.

[44]  G. Wilding,et al.  Concentration-dependent effects of fatty acids on warfarin binding to albumin. , 1977, Biochemical pharmacology.

[45]  G. Sudlow,et al.  Further characterization of specific drug binding sites on human serum albumin. , 1976, Molecular pharmacology.

[46]  G. Sudlow,et al.  The characterization of two specific drug binding sites on human serum albumin. , 1975, Molecular pharmacology.

[47]  C. Chignell,et al.  Optical studies of drug-protein complexes. V. The interaction of phenylbutazone, flufenamic acid, and dicoumarol with acetylsalicylic acid-treated human serum albumin. , 1971, Molecular pharmacology.

[48]  M. Oliver,et al.  Free fatty acids during acute myocardial infarction. , 1971, Progress in cardiovascular diseases.

[49]  C. Chignell Optical studies of drug-protein complexes. IV. The interaction of warfarin and dicoumarol with human serum albumin. , 1970, Molecular pharmacology.

[50]  C. Chignell Optical Studies of Drug-Protein Complexes , 1969 .

[51]  C. Chignell Optical studies of drug-protein complexes. II. Interaction of phenylbutazone and its analogues with human serum albumin. , 1969, Molecular pharmacology.

[52]  C. Chignell Optical studies of drug-protein complexes. 3. Interaction of flufenamic acid and other N-arylanthranilates with serum albumin. , 1969, Molecular pharmacology.

[53]  R. S. Gordon,et al.  The metabolism of albumin-bound C14-labeled unesterified fatty acids in normal human subjects. , 1958, The Journal of clinical investigation.